| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Models, Genetic | 9 | 2011 | 3499 | 1.190 |
Why?
|
| Models, Statistical | 11 | 2019 | 5081 | 1.130 |
Why?
|
| Likelihood Functions | 4 | 2018 | 1001 | 0.840 |
Why?
|
| Metabolic Diseases | 2 | 2020 | 653 | 0.830 |
Why?
|
| Multifactorial Inheritance | 4 | 2022 | 1148 | 0.820 |
Why?
|
| Genome-Wide Association Study | 12 | 2022 | 11952 | 0.810 |
Why?
|
| Software Validation | 1 | 2021 | 58 | 0.800 |
Why?
|
| Synteny | 1 | 2020 | 81 | 0.790 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2022 | 571 | 0.740 |
Why?
|
| Polymorphism, Single Nucleotide | 17 | 2020 | 15404 | 0.720 |
Why?
|
| HIV-1 | 22 | 2015 | 6854 | 0.620 |
Why?
|
| Genetic Loci | 3 | 2016 | 2560 | 0.590 |
Why?
|
| Gene Expression Profiling | 5 | 2020 | 9375 | 0.590 |
Why?
|
| Atrial Fibrillation | 3 | 2022 | 4827 | 0.520 |
Why?
|
| HIV Infections | 30 | 2019 | 16214 | 0.470 |
Why?
|
| Haplotypes | 5 | 2008 | 2776 | 0.470 |
Why?
|
| Anti-HIV Agents | 15 | 2015 | 4171 | 0.460 |
Why?
|
| Genotype | 14 | 2011 | 12882 | 0.450 |
Why?
|
| Bayes Theorem | 4 | 2020 | 2215 | 0.430 |
Why?
|
| Antiretroviral Therapy, Highly Active | 8 | 2012 | 1867 | 0.420 |
Why?
|
| Algorithms | 7 | 2021 | 13759 | 0.410 |
Why?
|
| Photoplethysmography | 2 | 2022 | 56 | 0.410 |
Why?
|
| Cardiovascular Diseases | 8 | 2022 | 14701 | 0.390 |
Why?
|
| Blood Sedimentation | 2 | 2022 | 225 | 0.390 |
Why?
|
| Dyslipidemias | 6 | 2022 | 840 | 0.370 |
Why?
|
| Brain Injuries | 4 | 2022 | 1986 | 0.370 |
Why?
|
| Obesity | 6 | 2022 | 12420 | 0.360 |
Why?
|
| Biostatistics | 1 | 2011 | 160 | 0.350 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2022 | 428 | 0.350 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2022 | 582 | 0.340 |
Why?
|
| Indinavir | 3 | 2003 | 74 | 0.320 |
Why?
|
| Research Design | 2 | 2021 | 5932 | 0.320 |
Why?
|
| Lipase | 5 | 2008 | 309 | 0.310 |
Why?
|
| Genomics | 3 | 2020 | 5562 | 0.290 |
Why?
|
| Observation | 1 | 2008 | 314 | 0.290 |
Why?
|
| CD4-Positive T-Lymphocytes | 11 | 2019 | 4338 | 0.290 |
Why?
|
| Genetic Association Studies | 2 | 2018 | 2691 | 0.280 |
Why?
|
| Humans | 84 | 2023 | 725001 | 0.280 |
Why?
|
| Longitudinal Studies | 5 | 2022 | 13692 | 0.280 |
Why?
|
| Disease | 1 | 2011 | 686 | 0.270 |
Why?
|
| Data Interpretation, Statistical | 3 | 2007 | 2726 | 0.270 |
Why?
|
| Computational Biology | 2 | 2015 | 3522 | 0.260 |
Why?
|
| Cervix Uteri | 3 | 2019 | 581 | 0.250 |
Why?
|
| Apolipoprotein C-III | 1 | 2006 | 203 | 0.250 |
Why?
|
| Virus Integration | 4 | 2015 | 298 | 0.250 |
Why?
|
| Interferon-alpha | 3 | 2013 | 894 | 0.250 |
Why?
|
| Regression Analysis | 2 | 2011 | 6434 | 0.250 |
Why?
|
| HIV Protease Inhibitors | 3 | 2006 | 429 | 0.250 |
Why?
|
| Mucous Membrane | 2 | 2019 | 667 | 0.240 |
Why?
|
| Macrophage Activation | 2 | 2017 | 564 | 0.240 |
Why?
|
| Cholesterol, LDL | 1 | 2013 | 2319 | 0.230 |
Why?
|
| Endotoxemia | 2 | 2017 | 205 | 0.230 |
Why?
|
| Myocardium | 1 | 2016 | 4811 | 0.220 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 2 | 2019 | 567 | 0.220 |
Why?
|
| Computer Simulation | 6 | 2017 | 6158 | 0.220 |
Why?
|
| CD4 Lymphocyte Count | 8 | 2014 | 2534 | 0.210 |
Why?
|
| Gene Dosage | 1 | 2007 | 1266 | 0.210 |
Why?
|
| Lipids | 2 | 2013 | 3299 | 0.210 |
Why?
|
| Vagina | 2 | 2019 | 793 | 0.210 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2019 | 2102 | 0.200 |
Why?
|
| Simian immunodeficiency virus | 2 | 2019 | 849 | 0.200 |
Why?
|
| Virus Replication | 5 | 2015 | 2546 | 0.200 |
Why?
|
| Databases, Genetic | 2 | 2020 | 1782 | 0.200 |
Why?
|
| Coma, Post-Head Injury | 1 | 2020 | 21 | 0.200 |
Why?
|
| Triglycerides | 2 | 2006 | 2519 | 0.190 |
Why?
|
| Consciousness Disorders | 2 | 2021 | 390 | 0.190 |
Why?
|
| Viral Load | 8 | 2015 | 3237 | 0.190 |
Why?
|
| Principal Component Analysis | 1 | 2023 | 940 | 0.190 |
Why?
|
| Heredity | 1 | 2020 | 155 | 0.190 |
Why?
|
| Prospective Studies | 12 | 2023 | 51853 | 0.180 |
Why?
|
| Phenotype | 8 | 2019 | 16262 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2020 | 17328 | 0.180 |
Why?
|
| Semen | 2 | 2019 | 303 | 0.180 |
Why?
|
| Leukocyte Count | 2 | 2022 | 1614 | 0.180 |
Why?
|
| Inflammation | 4 | 2021 | 10337 | 0.180 |
Why?
|
| C-Reactive Protein | 2 | 2022 | 3692 | 0.180 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2020 | 219 | 0.170 |
Why?
|
| Ferritins | 1 | 2022 | 582 | 0.170 |
Why?
|
| Female | 44 | 2023 | 375303 | 0.170 |
Why?
|
| Hospital Mortality | 3 | 2022 | 5222 | 0.170 |
Why?
|
| Blast Injuries | 1 | 2022 | 280 | 0.170 |
Why?
|
| Sampling Studies | 1 | 2020 | 631 | 0.170 |
Why?
|
| Electrocardiography | 2 | 2022 | 6404 | 0.170 |
Why?
|
| Adult | 33 | 2023 | 211523 | 0.170 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 1532 | 0.170 |
Why?
|
| Middle Aged | 30 | 2023 | 212155 | 0.160 |
Why?
|
| Male | 36 | 2023 | 346964 | 0.160 |
Why?
|
| Selection Bias | 1 | 2020 | 366 | 0.160 |
Why?
|
| Polyethylene Glycols | 2 | 2013 | 1179 | 0.150 |
Why?
|
| Hospitals, General | 1 | 2020 | 712 | 0.150 |
Why?
|
| Confidentiality | 1 | 2021 | 603 | 0.150 |
Why?
|
| Niacin | 1 | 2017 | 115 | 0.140 |
Why?
|
| Causality | 1 | 2022 | 1235 | 0.140 |
Why?
|
| Artificial Intelligence | 1 | 2008 | 1972 | 0.140 |
Why?
|
| Disease Progression | 4 | 2023 | 13161 | 0.140 |
Why?
|
| Aged | 20 | 2022 | 161379 | 0.140 |
Why?
|
| Dendritic Cells | 4 | 2015 | 2684 | 0.130 |
Why?
|
| Chemokine CX3CL1 | 1 | 2015 | 53 | 0.130 |
Why?
|
| Linkage Disequilibrium | 2 | 2017 | 1989 | 0.130 |
Why?
|
| Glutathione Transferase | 2 | 2007 | 602 | 0.130 |
Why?
|
| Macrophages | 3 | 2022 | 5693 | 0.130 |
Why?
|
| Probability | 1 | 2020 | 2485 | 0.130 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2007 | 416 | 0.120 |
Why?
|
| Disease Susceptibility | 3 | 2016 | 1761 | 0.120 |
Why?
|
| Linear Models | 3 | 2017 | 5934 | 0.120 |
Why?
|
| Biometry | 1 | 2017 | 561 | 0.120 |
Why?
|
| Open Reading Frames | 1 | 2017 | 819 | 0.120 |
Why?
|
| Military Personnel | 1 | 2022 | 1074 | 0.120 |
Why?
|
| Myocardial Infarction | 4 | 2016 | 11531 | 0.120 |
Why?
|
| Intensive Care Units | 3 | 2022 | 3584 | 0.110 |
Why?
|
| Hypothermia, Induced | 1 | 2018 | 745 | 0.110 |
Why?
|
| Lipopolysaccharides | 3 | 2022 | 2195 | 0.110 |
Why?
|
| DNA, Viral | 2 | 2012 | 2270 | 0.110 |
Why?
|
| Hospitalization | 5 | 2023 | 9956 | 0.110 |
Why?
|
| Pedigree | 1 | 2020 | 4630 | 0.110 |
Why?
|
| Language | 1 | 2021 | 1350 | 0.110 |
Why?
|
| Viremia | 5 | 2012 | 722 | 0.110 |
Why?
|
| Interferons | 1 | 2015 | 687 | 0.110 |
Why?
|
| Interleukin-6 | 1 | 2022 | 3152 | 0.100 |
Why?
|
| Body Composition | 1 | 2021 | 2416 | 0.100 |
Why?
|
| Bacterial Translocation | 1 | 2011 | 74 | 0.100 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2022 | 1396 | 0.100 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 465 | 0.100 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2011 | 66 | 0.100 |
Why?
|
| Brain Concussion | 1 | 2022 | 1262 | 0.100 |
Why?
|
| Cross-Sectional Studies | 8 | 2020 | 24043 | 0.100 |
Why?
|
| Endometrium | 1 | 2014 | 418 | 0.100 |
Why?
|
| Cholesterol, HDL | 2 | 2008 | 1797 | 0.100 |
Why?
|
| Protein Precursors | 1 | 2015 | 1147 | 0.100 |
Why?
|
| Meta-Analysis as Topic | 1 | 2016 | 1335 | 0.100 |
Why?
|
| Alternative Splicing | 1 | 2016 | 1116 | 0.100 |
Why?
|
| Gene Frequency | 2 | 2008 | 3584 | 0.100 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2018 | 1021 | 0.090 |
Why?
|
| Antiviral Agents | 2 | 2013 | 2896 | 0.090 |
Why?
|
| Resource Allocation | 1 | 2012 | 347 | 0.090 |
Why?
|
| Cohort Studies | 11 | 2023 | 39883 | 0.090 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2013 | 597 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2023 | 74145 | 0.090 |
Why?
|
| Inpatients | 1 | 2020 | 2392 | 0.090 |
Why?
|
| Cluster Analysis | 4 | 2009 | 2762 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2017 | 4799 | 0.090 |
Why?
|
| Anti-Retroviral Agents | 3 | 2009 | 1674 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 15454 | 0.080 |
Why?
|
| Statistical Distributions | 1 | 2008 | 66 | 0.080 |
Why?
|
| AIDS Serodiagnosis | 1 | 2009 | 182 | 0.080 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2008 | 114 | 0.080 |
Why?
|
| Autoantigens | 1 | 2012 | 885 | 0.080 |
Why?
|
| Immunity, Humoral | 1 | 2012 | 576 | 0.080 |
Why?
|
| Ketamine | 1 | 2013 | 483 | 0.080 |
Why?
|
| Antigens, Viral | 1 | 2012 | 1145 | 0.080 |
Why?
|
| RNA | 1 | 2017 | 2708 | 0.080 |
Why?
|
| Brucella abortus | 1 | 2006 | 12 | 0.080 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 254 | 0.080 |
Why?
|
| Brucellosis | 1 | 2006 | 18 | 0.080 |
Why?
|
| Aged, 80 and over | 6 | 2022 | 57615 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 800 | 0.080 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 2952 | 0.080 |
Why?
|
| Killer Cells, Natural | 3 | 2011 | 2105 | 0.080 |
Why?
|
| Benzoxazines | 1 | 2008 | 300 | 0.070 |
Why?
|
| Sex Factors | 1 | 2021 | 10385 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2022 | 3268 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 3169 | 0.070 |
Why?
|
| Risk Factors | 8 | 2022 | 70971 | 0.070 |
Why?
|
| Thyrotoxicosis | 1 | 2007 | 82 | 0.070 |
Why?
|
| Cerebral Hemorrhage | 1 | 2018 | 2570 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2020 | 11403 | 0.070 |
Why?
|
| Immunity, Innate | 3 | 2007 | 2936 | 0.070 |
Why?
|
| South Africa | 4 | 2011 | 1648 | 0.070 |
Why?
|
| Treatment Outcome | 8 | 2022 | 61674 | 0.070 |
Why?
|
| Health Resources | 1 | 2012 | 905 | 0.070 |
Why?
|
| Lipid Metabolism | 2 | 2011 | 1967 | 0.070 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2016 | 1637 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2015 | 4309 | 0.070 |
Why?
|
| Consciousness | 2 | 2020 | 554 | 0.070 |
Why?
|
| Plasmodium | 1 | 2007 | 242 | 0.060 |
Why?
|
| Apolipoprotein A-I | 1 | 2006 | 283 | 0.060 |
Why?
|
| Bacteremia | 1 | 2011 | 946 | 0.060 |
Why?
|
| Apolipoproteins | 1 | 2007 | 309 | 0.060 |
Why?
|
| Recovery of Function | 2 | 2021 | 2912 | 0.060 |
Why?
|
| Brain Ischemia | 1 | 2018 | 3206 | 0.060 |
Why?
|
| Interleukin-12 | 1 | 2006 | 593 | 0.060 |
Why?
|
| Electronic Health Records | 1 | 2020 | 4307 | 0.060 |
Why?
|
| Telemedicine | 1 | 2021 | 2733 | 0.060 |
Why?
|
| Nelfinavir | 1 | 2003 | 67 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 2215 | 0.060 |
Why?
|
| Receptors, CCR5 | 2 | 2019 | 498 | 0.060 |
Why?
|
| Genome, Human | 1 | 2016 | 4425 | 0.060 |
Why?
|
| Aging | 1 | 2022 | 8531 | 0.060 |
Why?
|
| Antibodies, Neutralizing | 1 | 2012 | 1901 | 0.050 |
Why?
|
| HIV | 2 | 2011 | 1563 | 0.050 |
Why?
|
| Leptin | 1 | 2010 | 1597 | 0.050 |
Why?
|
| Stavudine | 2 | 2012 | 84 | 0.050 |
Why?
|
| Lymphocyte Activation | 5 | 2015 | 5544 | 0.050 |
Why?
|
| Asthma | 1 | 2020 | 5838 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2020 | 23178 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2022 | 202 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2013 | 3014 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2006 | 673 | 0.050 |
Why?
|
| Adiposity | 1 | 2011 | 1785 | 0.050 |
Why?
|
| Molecular Sequence Data | 3 | 2006 | 18297 | 0.050 |
Why?
|
| Software | 1 | 2015 | 4404 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2002 | 461 | 0.050 |
Why?
|
| Saquinavir | 1 | 2000 | 29 | 0.050 |
Why?
|
| Young Adult | 4 | 2021 | 55791 | 0.050 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2011 | 1827 | 0.050 |
Why?
|
| Spleen | 1 | 2006 | 2376 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2003 | 13927 | 0.050 |
Why?
|
| Macaca mulatta | 2 | 2019 | 2389 | 0.050 |
Why?
|
| Intubation | 1 | 2020 | 136 | 0.050 |
Why?
|
| Ritonavir | 2 | 2012 | 303 | 0.050 |
Why?
|
| Respiratory Therapy | 1 | 2020 | 134 | 0.050 |
Why?
|
| Monocytes | 1 | 2009 | 2575 | 0.040 |
Why?
|
| Headache | 1 | 2007 | 1158 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2015 | 10006 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 12183 | 0.040 |
Why?
|
| Tuberculosis | 1 | 2011 | 1878 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2022 | 8099 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2016 | 11511 | 0.040 |
Why?
|
| Antipyretics | 1 | 2018 | 24 | 0.040 |
Why?
|
| Coma | 1 | 2022 | 455 | 0.040 |
Why?
|
| Multigene Family | 1 | 2002 | 1116 | 0.040 |
Why?
|
| Massachusetts | 2 | 2021 | 8555 | 0.040 |
Why?
|
| Malaria | 1 | 2007 | 1197 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2020 | 9837 | 0.040 |
Why?
|
| Boston | 2 | 2020 | 9287 | 0.040 |
Why?
|
| United States | 2 | 2022 | 68433 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2006 | 2894 | 0.040 |
Why?
|
| Drug Resistance, Viral | 1 | 2002 | 806 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 5522 | 0.040 |
Why?
|
| Drug Administration Schedule | 3 | 2012 | 4939 | 0.040 |
Why?
|
| Adolescent | 2 | 2023 | 84411 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2017 | 19487 | 0.030 |
Why?
|
| Fatigue | 1 | 2023 | 1488 | 0.030 |
Why?
|
| Stroke | 1 | 2018 | 9569 | 0.030 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2015 | 25 | 0.030 |
Why?
|
| Pakistan | 1 | 2016 | 290 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2018 | 732 | 0.030 |
Why?
|
| Waist-Hip Ratio | 1 | 2016 | 516 | 0.030 |
Why?
|
| Perforin | 1 | 2015 | 173 | 0.030 |
Why?
|
| Arousal | 1 | 2020 | 1163 | 0.030 |
Why?
|
| Axons | 1 | 2022 | 1685 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 4349 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2020 | 2613 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2016 | 3965 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2020 | 11885 | 0.030 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2015 | 456 | 0.030 |
Why?
|
| Prognosis | 4 | 2019 | 28718 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2022 | 4221 | 0.030 |
Why?
|
| HIV Protease | 2 | 2005 | 93 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 5342 | 0.030 |
Why?
|
| Logistic Models | 2 | 2020 | 13356 | 0.030 |
Why?
|
| Interferon-gamma | 2 | 2015 | 3221 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 1167 | 0.030 |
Why?
|
| Disease Reservoirs | 1 | 2012 | 135 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2022 | 2227 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2015 | 518 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2016 | 635 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2019 | 1614 | 0.030 |
Why?
|
| Midazolam | 1 | 2013 | 266 | 0.030 |
Why?
|
| Time Factors | 5 | 2015 | 40178 | 0.030 |
Why?
|
| Cytokines | 2 | 2019 | 7187 | 0.020 |
Why?
|
| Apoptosis | 2 | 2022 | 9754 | 0.020 |
Why?
|
| Fever | 1 | 2018 | 1561 | 0.020 |
Why?
|
| Plasma | 1 | 2014 | 564 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2011 | 5970 | 0.020 |
Why?
|
| Serum | 1 | 2011 | 214 | 0.020 |
Why?
|
| Lamivudine | 1 | 2011 | 334 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2005 | 14955 | 0.020 |
Why?
|
| Africa South of the Sahara | 1 | 2012 | 706 | 0.020 |
Why?
|
| Self Report | 1 | 2020 | 3410 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 2455 | 0.020 |
Why?
|
| Zidovudine | 1 | 2011 | 619 | 0.020 |
Why?
|
| Consensus | 1 | 2018 | 2821 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 2007 | 20448 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2021 | 3263 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2010 | 241 | 0.020 |
Why?
|
| Adipocytes | 1 | 2016 | 1190 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2013 | 694 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 2007 | 2901 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 12244 | 0.020 |
Why?
|
| Carbimazole | 1 | 2007 | 4 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 2001 | 0.020 |
Why?
|
| Alkynes | 1 | 2008 | 305 | 0.020 |
Why?
|
| Transfection | 1 | 2016 | 5963 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2021 | 34755 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 1718 | 0.020 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2006 | 27 | 0.020 |
Why?
|
| Antithyroid Agents | 1 | 2007 | 67 | 0.020 |
Why?
|
| Mutation | 4 | 2007 | 29645 | 0.020 |
Why?
|
| CD40 Ligand | 1 | 2009 | 530 | 0.020 |
Why?
|
| Cyclopropanes | 1 | 2008 | 415 | 0.020 |
Why?
|
| RNA Interference | 1 | 2016 | 2957 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2022 | 6009 | 0.020 |
Why?
|
| Malaria Vaccines | 1 | 2007 | 145 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2015 | 2253 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2009 | 762 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2007 | 525 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 632 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 1470 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2015 | 1987 | 0.020 |
Why?
|
| Comorbidity | 1 | 2020 | 10246 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2007 | 6881 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2021 | 6602 | 0.020 |
Why?
|
| Graves Disease | 1 | 2007 | 243 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2005 | 6196 | 0.020 |
Why?
|
| Registries | 1 | 2021 | 7910 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2011 | 1691 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2005 | 115 | 0.020 |
Why?
|
| Triage | 1 | 2012 | 962 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 3635 | 0.020 |
Why?
|
| Alleles | 1 | 2016 | 6940 | 0.020 |
Why?
|
| Brain | 2 | 2021 | 25743 | 0.020 |
Why?
|
| Smoking | 1 | 2021 | 8882 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2007 | 589 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 1403 | 0.010 |
Why?
|
| Mortality | 1 | 2015 | 2825 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2020 | 12527 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 6225 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6527 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 6669 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2012 | 19620 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2007 | 2205 | 0.010 |
Why?
|
| Pandemics | 1 | 2022 | 7859 | 0.010 |
Why?
|
| Markov Chains | 1 | 2005 | 976 | 0.010 |
Why?
|
| Quality of Life | 1 | 2022 | 12113 | 0.010 |
Why?
|
| Animals | 4 | 2019 | 168735 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2007 | 1611 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 18040 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 12318 | 0.010 |
Why?
|
| Selection, Genetic | 1 | 2005 | 902 | 0.010 |
Why?
|
| Lipoproteins | 1 | 2005 | 882 | 0.010 |
Why?
|
| Monte Carlo Method | 1 | 2005 | 1297 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2016 | 23445 | 0.010 |
Why?
|
| Mothers | 1 | 2009 | 2085 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 2935 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2007 | 1846 | 0.010 |
Why?
|
| Heterozygote | 1 | 2005 | 2822 | 0.010 |
Why?
|
| Glucose | 1 | 2010 | 4315 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 38720 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 19903 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 6440 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 4409 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 2000 | 888 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2012 | 4257 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 7835 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 6396 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 4249 | 0.010 |
Why?
|
| Models, Biological | 1 | 2012 | 9667 | 0.010 |
Why?
|
| Base Sequence | 1 | 2006 | 12981 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 10244 | 0.010 |
Why?
|
| Child | 2 | 2009 | 75163 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2004 | 9026 | 0.010 |
Why?
|
| Infant | 1 | 2011 | 34331 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2007 | 8896 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 22139 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 11303 | 0.000 |
Why?
|
| Mice | 1 | 2006 | 80318 | 0.000 |
Why?
|